Karen R. Rabin, MD, PhD

Location

  • Texas Medical Center

Specialty

Cancer

Phone: 832-824-4213
Fax: 832-825-1206

Contact Information

1102 Bates Ave.
Suite 750.01
Houston, TX 77030
United States
Texas

Research Laboratory

Director, Leukemia Program

Education

School Education Degree Year
Lucile Packard Children's Hospital fellowship Pediatric Hematology Oncology 2004
University of California San Francisco residency Pediatrics 2001
University of California, San Francisco medical school Doctor of Medicine 1998
Baylor College of Medicine university

About

Dr. Karen Rabin is Director of the Leukemia Program. Her clinical interests include: leukemia, lymphoma, the molecular genetics of ALL, and ALL in patients with Down syndrome.

Organization

Organization Name Role
American Association of Pediatrics (AAP) Member
American Society of Hematology (ASH) Member
American Society of Pediatric Hematology and Oncology (ASPHO) Member
Children's Oncology Group (COG) Member

Research Statement

Dr. Karen Rabin's principal research interest is in the biology of acute lymphoblastic leukemia (ALL) in children with Down syndrome, including the molecular basis for leukemogenesis in these patients, the basis for their increased risk of treatment-related toxicities, and identification of novel therapeutic targets. Dr. Rabin also has a research interest in molecular determinants associated with prognosis in pediatric ALL, and is Co-Chair of the Children's Oncology Group ALL Classification Study AALL08B1.

Dr. Karen Rabin has nationally-recognized expertise in the management of childhood acute lymphoblastic leukemia (ALL).  She serves as the Co-Chair of the Children’s Oncology Group ALL Classification Study AALL08B1, which determines the appropriate risk group assignment and therapy for over 2,000 children diagnosed with ALL each year.  She is also the COG Principal Investigator for Baylor College of Medicine, with responsibility for the oversight of all COG clinical trials conducted at this site.

Dr. Rabin’s laboratory research focuses on the biology of acute lymphoblastic leukemia (ALL) in children with Down syndrome, including the molecular basis for leukemogenesis in these patients, the basis for their increased risk of treatment-related toxicities, and identification of novel therapeutic targets.

Research Interests
Down syndrome ALL
Molecular basis for leukemogenesis
Increased risk of treatment-related toxicities
Identification of novel therapeutic targets
Molecular determinants associated with prognosis in pediatric ALL

Selected Publications